Skip to main content

Advertisement

Table 3 Changes between baseline and endpoint in metabolic and laboratory markers in the two groups

From: A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

Variables Dapagliflozin (n = 14) DPP-4 inhibitors (n = 15) Change difference between groups p value
Mean change (95% CI) Mean change (95% CI)
HbA1c (%) 0.48 (0.17 to 0.79)†† 0.24 (−0.13 to 0.61) 0.30
Glycated albumin (%)a 1.04 (−0.14 to 2.21) 0.55 (−0.91 to 2.01) 0.58
Body mass index (kg m−2) −0.90 (−1.42 to −0.39)†† 0.12 (−0.12 to 0.36) 0.001
Systolic BP (mmHg)b −2.8 (−11.5 to 5.8) 4.5 (−5.7 to 14.6) 0.25
Diastolic BP (mmHg)b 4.1 (−3.2 to 11.4) 2.0 (−2.9 to 6.9) 0.61
Hemoglobin (g dL−1)a 0.44 (0.05 to 0.83) 0.01 (−0.43 to 0.47) 0.13
Hematocrit (%)a 1.61 (0.46 to 2.77) −0.23 (−1.61 to 1.15) 0.04
ALT (U L−1) −2.0 (−26.0 to 6.0) 1.0 (−4.0 to 11.0) 0.03
Uric acid (mg dL−1) −0.54 (−1.10 to 0.03) 0 (−0.37 to 0.32) 0.11
Estimated GFR [mL min−1 (1.73 m2)−1] 1.3 (−11.7 to 9.0) 3.0 (−4.9 to 13.6) 0.42
Log UACRa −0.16 (−0.32 to 0) 0.04 (−0.10 to 0.17) 0.05
  1. Values are mean ± SD or median (25–75% CI). P values: mean changes from baseline to the end of the study between the Dapagliflozin group and the DPP-4 inhibitors group.  P < 0.05 and †† P < 0.01 between baseline and the end of the study, (paired t test or Wilcoxon signed-rank test).  Mann–Whitney U test
  2. BP blood pressure, ALT alanine-aminotransferase, LDL low-density lipoprotein, HDL high-density lipoprotein, GFR glomerular filtration rate, UACR urine albumin to creatinine ratio
  3. aData from 28 patients
  4. bData from 27 patients